NDC 43598-581-01 - Buprenorphine and Naloxone
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 43598-581
- Requested NDC
- 43598-581-01
- Package NDCs from labels
- 43598-581-01, 43598-581-30
- Manufacturer
- Dr.Reddys Laboratories Inc | LTS Lohmann Therapy Systems Corp. | Pharmaron Manufacturing services (UK) LTD
- Effective date
- 2026-01-12
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Buprenorphine and Naloxone | Dr.Reddys Laboratories Inc | LTS Lohmann Therapy Systems Corp. | Pharmaron Manufacturing services (UK) LTD | 2026-01-12 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 43598-581-01 | Buprenorphine and Naloxone | 1 in 1 POUCH | FILM, SOLUBLE | 1 | 11 | |
| 43598-581-30 | Buprenorphine and Naloxone | 30 in 1 CARTON | FILM, SOLUBLE | 30 | 11 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 43598-581-01 | EA - Each | 43598-581 | 60f82d87-d0ad-4d84-930e-4910e6b1352d | 1 | 2019-03-12 |
| 43598-581-30 | EA - Each | 43598-581 | 4964c819-812a-46b9-a7d0-9e09fb6a87d9 | 1 | 2019-03-12 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Buprenorphine | BUPRENORPHINE | Actavis Pharma, Inc. | 03819118-86f6-4329-adaf-4599e7b71f46 | 2026-05-25 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Alka-Seltzer Original | ANHYDROUS CITRIC ACID, ASPIRIN, AND SODIUM BICARBONATE | Select Consumer Group | 3ca80d74-1e8b-49d9-e063-6394a90a4312 | 2026-05-24 | Warnings | XF417D3PSL |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | REMEDYREPACK INC. | 072b2c2e-a564-4bb4-8954-9349a7923807 | 2026-05-22 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Bryant Ranch Prepack | b9b5b1d5-482e-42ad-aabd-869e9ade5126 | 2026-05-14 | Warnings, Adverse reactions | 56W8MW3EN1 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Bryant Ranch Prepack | a0f8c28c-ed9a-4a26-91a3-b996c117ac2c | 2026-05-14 | Warnings, Adverse reactions | 56W8MW3EN1 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Bryant Ranch Prepack | d25b1a73-9794-4e86-82eb-dee3f159a214 | 2026-05-13 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Sodium Phosphates | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE AND SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | Hospira, Inc. | 6f044d16-295e-43ff-72a3-b045c387bc5c | 2026-05-11 | Warnings, Adverse reactions | 22ADO53M6F |
| Market Basket Effervescent Antacid and Pain Relief | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Demoulas Super Markets, Inc. | e15439c7-0e3c-7752-e053-2995a90a1a40 | 2026-05-11 | Warnings | XF417D3PSL |
| Meijer Effervescent Antacid and Pain Relief | ASPIRIN, ANHYDROUS CITRIC ACID, SODIUM BICARBONATE | Meijer Distribution Inc | 7305972b-aa0f-4daa-e053-2991aa0adfd7 | 2026-05-11 | Warnings | XF417D3PSL |
| BUPRENORPHINE | BUPRENORPHINE | Rhodes Pharmaceuticals LLC | da90618a-5621-4b15-bc48-9dcc631418de | 2026-05-04 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Rhodes Pharmaceuticals LLC | 794724a6-0fba-bc8d-ecdb-9e3be8ea2191 | 2026-05-01 | Warnings, Adverse reactions | 56W8MW3EN1 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Golden State Medical Supply, Inc. | 4f6e0056-b19d-0d0e-e063-6294a90a16e5 | 2026-04-24 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Redpharm Drug | 5005a6c8-9a3b-a99a-e063-6294a90aac13 | 2026-04-22 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Bryant Ranch Prepack | 63aaa6cc-8574-4990-8239-6fdeffce92c8 | 2026-04-16 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Unit Dose Solutions, Inc. | 4f979409-f9a2-d3a2-e063-6394a90accd0 | 2026-04-16 | Warnings, Adverse reactions | 56W8MW3EN1 |
| CLENPIQ | SODIUM PICOSULFATE, MAGNESIUM OXIDE, AND ANHYDROUS CITRIC ACID | Ferring Pharmaceuticals Inc. | e95fff66-4ec0-4001-a727-33e66a5ec7d5 | 2026-04-15 | Warnings, Adverse reactions | XF417D3PSL |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Aveva Drug Delivery Systems Inc. | cb112448-49a1-4209-bcdb-7cfae6501f51 | 2026-04-07 | Warnings, Adverse reactions | 1307056 1307061 56W8MW3EN1 |
| Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate | DIBASIC SODIUM PHOSPHATE, MONOBASIC POTASSIUM PHOSPHATE AND MONOBASIC SODIUM PHOSPHATE | Rising Pharma Holdings, Inc. | b01eac95-dbe3-4b21-a922-187e0fc8ad23 | 2026-04-07 | Adverse reactions | 22ADO53M6F |
| BUPRENORPHINE | BUPRENORPHINE | Bryant Ranch Prepack | cd0a90c6-32cc-4114-8573-86ac85503bdf | 2026-04-03 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine HCl and Naloxone HCl | BUPRENORPHINE AND NALOXONE | Bryant Ranch Prepack | 2aaad1a7-a0fd-4dd5-bb53-03afad8f10b9 | 2026-04-03 | Warnings, Adverse reactions | 56W8MW3EN1 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.